1. Home
  2. Vol 52, No 1 (2020)
  3. Siane

Comparative Effectiveness of Tuberculosis Treatment Daily versus Intermittent Regimen in Indonesian TB-DM Patients: Real World Patient Database Study

Angelina Siane, Purwantyastuti Ascobat, Instiaty Instiaty, Heidy Agustin

Abstract


Background: diabetes mellitus (DM) increases the risk of active TB by three times; there is no specific treatment strategy for tuberculosis-DM (TB-DM) patients. The 2017 WHO guidelines no longer recommended an intermittent regimen in the advanced phase of TB treatment due to higher risk of failure, relapse, and drug resistance compared to the daily regimen. This study aims to compare the effectiveness of treatment, in terms of clinical response and sputum conversion, of TB-DM patients in the advanced phase between the two-treatment delivery schedules. Methods: a retrospective cohort study from the medical records of patients from 1 January 2015 to 31 December 2018 at Persahabatan Hospital, Jakarta. The inclusion criteria are TB-DM patients aged >18 years with non-reactive HIV test, who have entered the advanced phase of category 1 TB treatment with smear positive at the time of diagnosis. Results: a total of 72 patients met the inclusion criteria. (75% male and 88.8% had at least 1+ smear results at the time of diagnosis). Thirty subjects still have positive smear at the beginning of the advance phase of treatment. After the advanced phase, 44.2% in the intermittent and 41.4% in the daily group were curedhaving sputum conversion. Seven subjects had side effects; but there were lots of dropouts and it is unclear whether they dropped because of side effects or not. Conclusion:there is no difference between sputum conversion profile and treatment success in advanced phase TB-DM treatment category 1 between the daily and intermittent regimen.ly for diabetic patients.

 


Keywords


TB-DM; diabetes mellitus; advanced phase; intermittent treatment; daily treatment; treatment success

References


Tuberculosis (TB). Data and statistics. Available at: https://www.cdc.gov/tb/statistics/default.htm. Accessed august 28th, 2018.

Global Tuberculosis Report 2018. Geneva: World Health Organization. 2018.

Gunda DW, Nkandala I, Kavishe GA, Kilonzo SB, Kabangila R, Mpondo BC. Prevalence and risk factors of delayed sputum conversion among patients treated for smear positive PTB in Northwestern rural Tanzania: A retrospective cohort study. J Trop Med. 2017;2017:5352906.

Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-46.

Sidibe EH. Main complications of diabetes mellitus in Africa. Ann Med Interne (Paris). 2000;151(8):624-8.

Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45(4):428-35.

Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health. 2010;15(11):1300-14.

Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol. 2008;167(12):1486-94.

Lee PH, Fu H, Lai TC, Chiang CY, Chan CC, Lin HH. Glycemic control and the risk of tuberculosis: a cohort study. PLoS Med. 2016;13(8):e1002072.

Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.

Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013;68(3):214-20.

Dooley K, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80(4):634-9.

Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2(9):740-53.

Faurholt-Jepsen D, Range N, Praygod G, et al. The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from Mwanza, Tanzania. BMC Infectious Diseases. 2012;12:165.

Isbaniyah F, Thabrani Z, Soepandi PZ, et al. Pedoman Diagnosis & Penatalaksanaan Tuberkulosis di Indonesia (KONSENSUS TB). Jakarta: Perhimpunan Dokter Paru Indonesia. 2011.

Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 Update. Geneva: World Health Organization. 2017.

Azarkar Z, Sharifzadeh G, Ebrahimzadeh A, Olumi S. Time to Sputum smear conversion in smear-positive pulmonary tuberculosis patients and factors for delayed conversion. Iran J Med Sci. 2016;41(1):44-7.

Cho NH, Kirigia J, Mbanya JC, et al. IDF Diabetes Atlas – 8th Edition. In: Karuranga S, Fernandes JdR, Huang Y, Malanda B, eds. International Diabetes Federation. 2017.

Jinda HA, Bhatt B, Malik JS. A study on the smear conversion time and its associated factors in sputum positive Category I Tuberculosis DOTS cases in district Rohtak, Haryana. Sch J App Med Sci. 2015;3(9D):3391-9.

Fonkeng LS, Ali IM, Noubom M, et al. Prevalence, predictors and treatment outcome of type 2 diabetes among newly diagnosed sputum positive pulmonary tuberculosis patients in Western Cameroon. J Infect Dis Epidemiol. 2017;3(2):1-13.

Salindri AD, Sales RF, DiMiceli L, Schechter MC, Kempker RR, Magee MJ. Isoniazid monoresistance and rate of culture conversion among patients in the State of Georgia with confirmed tuberculosis, 2009-2014. Ann Am Thorac Soc. 2018;15(3):331-40.

Konsensus Pengelolaan Tuberkulosis dan Diabetes Melitus (TB-DM) di Indonesia. Jakarta: Kementerian Kesehatan RI - Direktorat jenderal pengendalian penyakit dan penyehatan lingkungan, Direktorat pengendalian penyakit tidak menular. 2015.

Mi F, Tan S, Liang L, Harries AD, et al. Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China. Trop Med Int Health. 2013;18(11):1379-85.

Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the anti-tubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients. J Clin Diagn Res. 2013;7(2):292-5.


Full Text: PDF

Refbacks

  • There are currently no refbacks.